Skip to content
Peptigraph home

How to Inject TB-500: Sites, Syringes and Steps

Where to inject TB-500, which syringe to use, how to read units and the hygiene steps that prevent infection.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureSynthetic fragment of thymosin beta-4Updated
This is a general guide to subcutaneous injection, not a substitute for being shown by a nurse, pharmacist or doctor.

Injection sites

Most peptides are injected under the skin (subcutaneously), into the fatty layer rather than the muscle.

  • Belly: at least 2 inches (5 cm) away from the navel.
  • Front and outer thighs.
  • Back of the upper arms, if someone else can reach it.
  • Rotate sites each time and avoid skin that is bruised, scarred or irritated.

Syringe and needle

U-100 insulin syringes are marked in units: 100 units equal 1 mL, so 10 units is 0.1 mL. They come in 0.3, 0.5 and 1 mL sizes; a smaller syringe has finer marks and is easier to read for small doses. Needle length and gauge used for TB-500 in studies: not reported in study abstracts (PubMed search, 11 Oct 2026).

How to read an insulin syringe

Step by step

  1. 1Wash your handsUse soap and water, and work on a clean surface.
  2. 2Check the vialLabel, lot and date present; solution clear with no particles. Mixing a powder vial first? Use sterile bacteriostatic water.
  3. 3Clean the vial top and the siteWipe both with an alcohol swab and let them dry.
  4. 4Draw the dosePull the plunger to the units mark for your dose, then tap out air bubbles and re-check the mark.
  5. 5InjectPinch a fold of skin, insert the needle at 45 to 90 degrees, push the plunger slowly and wait a few seconds before withdrawing.
  6. 6Dispose safelyPut the used syringe straight into a sharps container. Never reuse or share needles.
How to reconstitute a peptide vial

TB-500 in veterinary and doping-control papers

A doping-control paper describes TB-500 as a veterinary preparation containing a synthetic version of the peptide LKKTETQ.[12]

After a single TB-500 dose in horses, the N-acetylated LKKTETQ peptide and its metabolites were confirmed in equine urine and plasma.[12]

Rodent injection data

A rat study of Achilles tendon repair gave TB-500, alone or with BPC-157, by intraperitoneal injection after surgery.[13]

Its authors call it an exploratory rat study and its findings preliminary, pending dose-optimization and longer-term studies.[13]

In mice given thymosin beta-4 by intraperitoneal injection, serum levels rose from 2 minutes and stayed up for 40 minutes.[14]

Human studies used full-length thymosin beta-4, intravenously

A phase I trial of recombinant human thymosin beta-4 gave it by single and multiple intravenous injections to healthy volunteers, 54 in seven cohorts.[15]

The trial reports no obvious accumulation after continuous administration. It tested thymosin beta-4 itself, not TB-500.[15]

Regulatory text that applies to the injectable

Drugs@FDA returns no match for TB-500, so there is no label with administration instructions.[16]

FDA's safety-risk text for the TB-500 fragment says it found no human exposure data for products containing it.[17]

FDA's advisory-committee agenda lists TB-500 (free base and acetate) under wound healing.[18]

On WADA's list, TB-500 appears as the example beside thymosin-beta-4 and its derivatives.[19]

Common questions

Where do you inject TB-500?

No injection site is given in any human source here. The rat tendon study used intraperitoneal injection.[13]

What syringe is used for TB-500?

Vials are usually drawn with a U-100 insulin syringe, where 100 units equal 1 mL. Common sizes hold 0.3, 0.5 or 1 mL. Match the syringe to the dose so the mark is easy to read.

How often is TB-500 injected?

The interval comes from the study or prescription, not from this guide. See the dosage page for what studies used.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a short acetylated fragment; the human trials tested the full-length protein.[12]

Is TB-500 tested in athletes?

It is on WADA's list as a thymosin-beta-4 derivative. The only detection work cited here is a method validated in horse urine and plasma.[19]

More on TB-500

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) (1199 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  4. 4PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (humans[mh] OR patients[tiab]) (678 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (randomized[tiab] OR clinical trial[pt]) (18 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (wound[tiab] OR dermal[tiab] OR skin[tiab] OR hair[tiab]) (212 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (tendon[tiab] OR muscle[tiab] OR cardiac[tiab] OR myocardial[tiab] OR heart[tiab]) (246 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: "TB-500"[tiab] OR TB500[tiab] OR "Ac-LKKTETQ"[tiab] (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab] OR RGN-259[tiab] OR RGN-137[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (61 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  11. 11PubMed search: ("RGN-259"[tiab] OR "RGN-137"[tiab] OR "thymosin beta 4"[tiab]) AND (eye[tiab] OR ophthalmic[tiab] OR neurotrophic[tiab] OR cornea*[tiab]) AND (patients[tiab] OR trial[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  12. 12Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.Journal of chromatography. A · 2012PMID 23084823Accessed 2 Oct 2026
  13. 13Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
  14. 14Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major organs of mice.International journal of immunopharmacology · 1997PMID 9226473Accessed 2 Oct 2026
  15. 15A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.Journal of cellular and molecular medicine · 2021PMID 34346165Accessed 2 Oct 2026
  16. 16Drugs@FDA (openFDA) search: active ingredient "TB-500"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  17. 17Official web pageOfficial web page · web page
  18. 18Official web pageOfficial web page · web page
  19. 19World Anti-Doping Code International Standard Prohibited List 2026 (in effect 1 January 2026)World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026

Found an error? Report a correction.